Andreas Hägebarth

发表

Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines

I. Kovalenko, Andrea Glasauer, L. Schöckel, 2016, PloS one.

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models

Andreas Hägebarth, Ningshu Liu, O. Politz, 2017, International journal of cancer.

Expression analysis of proline rich 15 (Prr15) in mouse and human gastrointestinal tumors

H. Himmelbauer, Andreas Hägebarth, K. Patra, 2011, Molecular carcinogenesis.

Evidence for an alternative fatty acid desaturation pathway that increases 1 metabolic plasticity in cancer cells 2

B. Faubert, R. Deberardinis, Kwok-Kin Wong, 2019 .

Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth

Andrea Glasauer, L. Schöckel, Andreas Hägebarth, 2015, Cancer & metabolism.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Clara D. Christ, E. Nevedomskaya, H. Briem, 2021, Cellular Oncology.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

Clara D. Christ, E. Nevedomskaya, H. Briem, 2021, Cellular Oncology.

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity

B. Faubert, R. Deberardinis, Kwok-Kin Wong, 2019, Nature.

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity

B. Faubert, R. Deberardinis, Kwok-Kin Wong, 2019, Nature.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

A. Kamburov, A. Schlicker, Andreas Hägebarth, 2018, Molecular Cancer Therapeutics.

Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin

Andreas Hägebarth, D. Zopf, M. Ocker, 2015 .